Showing results (131-140 of 686) with videos related to
Sort By:
Pageof 69
American Journal of Physiology. Gastrointestinal and Liver Physiology|December 21, 2000
Systemic and portal hemodynamic effects of anandamideN Garcia, Z Járai, F Mirshahi, et al.Frontiers in Endocrinology|December 12, 2022
Nonalcoholic fatty liver disease is specifically related to the risk of hepatocellular cancer but not extrahepatic malignanciesSomaya Albhaisi, Donna McClish, Le Kang, et al.Expert Opinion on Drug Metabolism & Toxicology|October 21, 2016
Drug-induced steatohepatitisAjit Dash, Robert A Figler, Arun J Sanyal, et al.Journal of Hepatology|July 14, 2019
Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLDMary E Rinella, Frank Tacke, Arun J Sanyal, et al.Plos One|October 3, 2012
Metabolomic profiling to identify predictors of response to vitamin E for non-alcoholic steatohepatitis (NASH)Jianfeng Cheng, Andrew Joyce, Katherine Yates, et al.Journal of Hepatology|January 20, 2025
Modeling the health and economic impact of pharmacologic therapies for MASLD in the United StatesCarolyn Wallace, Ivane Gamkrelidze, Chris Estes, et al.Metabolism: Clinical and Experimental|March 22, 2016
Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver diseaseManoela Mota, Bubu A Banini, Sophie C Cazanave, et al.Hepatology (Baltimore, Md.)|August 13, 2017
Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of diseaseChris Estes, Homie Razavi, Rohit Loomba, et al.Therapeutic Advances in Gastroenterology|October 5, 2018
Rifaximin has the potential to prevent complications of cirrhosisSteven L Flamm, Kevin D Mullen, Zeev Heimanson, et al.Hepatology (Baltimore, Md.)|July 10, 2019
Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLDMary E Rinella, Frank Tacke, Arun J Sanyal, et al.Pageof 69